Suppositories for treating proctologic and gynecologic diseases |
||||||||||||||||||
|
IPC classes for russian patent Suppositories for treating proctologic and gynecologic diseases (RU 2421210):
Capillary protector / 2414230
Invention refers to pharmaceutical industry. A capillary protector containing dihydroquercetin and lipoic acid taken in a certain ratio.
Method for recombinant erythropoietin correction of endothelial dysfunction in l-name induced nitrogen oxide deficiency / 2409873
Endothelial dysfunction is stimulated in laboratory animal by intraperitoneal introduction of N-nitro-L-arginine methyl ether in dosage 25 mg/kg daily for seven days. The dysfunction severity is estimated by a relation of endothelium-independent and endothelium-dependent vasodilatation indices. Endothelial dysfunction is corrected by subcutaneous introduction of recombinant erythropoietin in dosage 50 IU/kg for the first, third and fifth days of experiment in the morning.
Germicide / 2402336
Invention refers to medicine and biology, particularly to biological preparations and can find application for healing of wounds, burns, treatment of tumours and correction of metabolic processes. In a germicide containing powder metal particles, as a metal, copper is used that represents a suspension in 0.9% NaCl of powder particles prepared of coarse metal particles exposed to plasma stream at temperature 5000°-6000°K, particle size 30-40 nm and suspension concentration 0.001 mg/ml.
Method of treating neurovascular complications of diabetes / 2402325
Invention refers to medicine, namely to endocrinology, and concerns treating neurovascular complications of diabetes. That is ensured by the additional administration of Mildronat in dosage 1000 mg a day with underlying baseline therapy consisting in the introduction of antihyperglycemic drugs, ACE inhibitors and antioxidants. Mildronat is introduced intravenously 30 minutes and orally 60 minutes prior to the introduction of the disease-modifying agents.
 Water-soluble inclusion complex of dihydroquercetin-β-cyclodextrin and method for preparing thereof / 2396077
Application: refers to medicine. A water-soluble inclusion complex of dihydroqercetin- β-cyclodextrin is characterised by the molar ratio of the specified components 1:1. Natural dihydroqercetin reacts with β-cyclodextrin in an aqueous deionised medium in boiling; filtering of the prepared product, crystallisation by progressive cooling with a dehydrating agent added and keeping to complete crystallisation, decantation of a mother solution, water flushing of the formed crystals, filtering and vacuum drying.
 Benzene derivative or salt thereof / 2395496
Invention relates to novel benzene derivatives of general formula (I) or salts thereof: [Chem. 12]
Pharmaceutical composition for treating vascular complications of diabetes and diabetic polyneuropathy / 2381034
Combined preparation containing thioctic acid in amount 100 to 1000 mg and dalargin in amount 0.1 to 4 mg is applied. The method of treating vascular complications of diabetes and diabetic polyneuropathy implies application of intravenous infusion of thioctic acid and dalargin in a pharmaceutically acceptable solvent within 2 courses of 10 days with a two-week interval. The preferential version of the composition is that one containing thioctic acid (300-600 mg), dalargin 3 mg and physiologic saline (250 ml). Application of the invention allows for prompt reduction or complete elimination of morbidity of vascular complications of diabetes and diabetic polyneuropathy.
 Preparation of mixture of flavonoids with free b-ring and flavans as therapeutic agent / 2379031
Claimed invention relates to chemical-pharmaceutical industry and concerns pharmaceutical composition for prevention and treatment of diseases and disease states connected with metabolic pathways of cycloxygenase-2 (CG-2) and 5-lipooxygenase (5-LO), which contains mixture of extract obtained from Scutellariae and enriched with flavonoids with free B-ring, which include baicalein, and extract obtained from Acacia and enriched with flavans, which include catechine and epicatechine. Claimed invention also relates to method of body weight loss and control over glucose level in blood. Methods by claimed invention include introduction to person, who needs it, of efficient amount of composition by claimed invention together with pharmaceutically acceptable carrier. Claimed invention mainly relates to prevention and treatment of diseases and states connected with metabolic pathways of cycloxygenase-2 (CG-2) and 5-lipooxygenase (5-LO), including, but not confining to it, stopping discomfort and pain in joints, induced by such states as osteoarthritis, rheumatoid arthritis and other injuries caused by overload.
Composition for treating chronic venous insufficiencies, containing aqueous extract of red grape leaves and antiinflammatory agent / 2367464
External composition for preventing and/or relieving the mild/moderate chronic venous insufficiency (CVI) of legs containing as a pharmaceutical reactant, the aqueous solution of red grape leaves and an antiinflammatory agent. Application of the composition to prepare a pharmaceutical product or a therapeutic cosmetic product to prevent and/or relieve mild/moderate chronic venous insufficiency (CVI) of legs.
Prevention method of venous thromboembolic disorders in elective operations of chronic venous insufficiency of lower limbs / 2360684
Invention refers to medicine, particularly to vascular surgery, and can be used for prevention of complications following phlebectomy operation. It is ensured by intramuscular introduction of Sulodexide daily within 5 days, once a day, in a dose 600 "ЕВД". The first introduction is carried out 2 hours prior to operation and the following ones - within 4 days after operation.
 Method of treating urogenital infection of lower parts of genital tracts in women / 2420274
Invention relates to medicine, namely to gynecology, and can be used in treatment of urogenital infection of lower parts of genital tracts in women. For this purpose carried out are per oral antibiotic therapy and additional irrigation with oxygenated solution of antimicrobial preparations for 1-3 min in volume 50-100 ml. Course constitutes 1-2 procedures per day for 3-7 days.
Method of preventing endometritis after cesarean section / 2412729
Invention relates to medicine, namely to operational obstetrics, and can be used for prevention of endometritis after Cesarean section. For this purpose irrigation of vagina with 0.25% water solution of chlorhexidine bigluconate in amount 150-200 ml is carried out 1-1.5 h before operation of planned Cesarean section and during 3-5 days after operation 2 times per day in the morning and in the afternoon.
Composition and method to control and maintain bacterial microflora and acidity of vagina / 2409368
Invention relates to medicinal agents and to application of benzoic acid and/or its sodium salt in combination with saccharide (saccharides) as active components to make vaginal composition, to stimulate growing number of gram-positive bacilli and production of acids in vagina, in case gram-positive bacilli in vagina are scarce, and vagina acidity is far too weak, and to inhibit production of acids into vagina, in case of high number of gram-positive bacilli in vagina and excessive acidity of vagina, by maintenance of vaginal secretion pH value in the range from 3.5 to 4.5. Also vaginal composition is described, as well as method to control microflora and acidity of vagina.
Method for treatment of anogenital warts / 2404743
Invention relates to medicine, in particular to dermatovenerology and gynaecology and to treatment of anogenital warts. For this purpose 30% glicifon ointment is applied onto lesion foci. Ointment is applied daisy in a thin layer for 6-8 hours. Course of treatment is 5-14 days.
Pharmaceutical composition for treating urogenital infections / 2401102
Offered pharmaceutical composition for treating urogenital infections in a unit dosage form contains antiseptics, a biologically active additive, an ingredient for natural vaginal acidity, an antifungal agent, an anesthetic and a base. Even in minimum dosage, the pharmaceutical composition exhibits an effective action for treating urogenital infections since it has a wide spectrum of antimicrobial action, such as antiseptic and antifungal, removes painful symptoms of urogenital infections, normalises a disturbed microflora and ensures a regenerative effect.
Method of treating bacterial vaginosis / 2393870
Invention refers to medicine, particularly to gynecology, and concerns treating bacterial vaginosis. That is ensured by administration of a herbal tincture containing camomile flowers, pine buds, birch buds, celandine herb, bird cherry, oak bark and alder collective fruits at the equal ratio, dosed 250.0 ml once a day. Additionally, sterile tissues wetted in said tincture are introduced intravaginally. The therapeutic course is 20 days.
Method of acute bacterial vaginitis treatment / 2391977
Invention belongs to medicine, notably to gynaecology and dermatovenerology, and concerns treating of acute bacterial vaginitis. Before suppository insertion vagina must be treated with cotton or gauze pad soaked with 30-50 ml of Tantum Rosa solution. Vaginal suppository Bifilis must be inserted in the morning and midday, and suppository Syntomycin must be inserted in the evening. Course of treatment lasts 5-7 days.
 Method of treating chronic recurrent urogenital bacterial and viral diseases / 2390339
Invention refers to medicine, particularly to gynaecology and urology, and concerns treating chronic recurrent urogenital bacterial and viral infections. That is ensured by producing lymphocyte self-cells of the patient's blood. Then said lymphocytes are cultivated with an immunomodulator. It is followed with intrauterine introduction of 0.5-2.0 ml of a lymphocyte suspension in an acceptable medium at their concentration 106-107 cel/ml.
Method of treating allergic dermatosis / 2389492
Invention relates to medicine, particularly to dermatology and to allergology, and concerns treating allergic dermatosis. That is ensured by etiotropic and nosotropic pharmacotherapy. It is combined with the analysis of vaginal flora for dysbacteriosis. If any, treatment is correlated with the detected pathology. At first, the antibacterial therapy is used to suppress pathogenic flora. Then it is followed with the therapy used to recover normal vaginal flora.
Vaginal compositions for infection treatment / 2385720
Invention concerns medicine, particularly to gynaecology, and covers therapy of vaginal infections. The offered method of vaginal infection treatment involves the stages of cleaning and cooling of a woman's perineum by applying a wet substratum containing a coolant and the stage of treatment by introduction of an active antimycotic component into vagina.
Pharmaceutical composition containing hyaluronidase and liposomes for external application / 2417097
Invention refers to pharmacy, namely to a pharmaceutical composition for local application, containing enzyme hyaluronidase which can be used in pharmacy for treatment and prevention of inflammatory prostate diseases, such as prostatitis. The pharmaceutical composition for local application contains as an active ingredient hyaluronidase 2.44 wt %, Tween-80 2.93 wt %, PEG-1500 91.69 wt %, liposome 2.44 wt %, and pharmaceutically acceptable carriers or excipients, such as benzydamine 0.5 wt %.
|
FIELD: medicine. SUBSTANCE: invention refers to suppositories for treating proctologic and gynaecologic diseases. Said suppositories contain a drug in the form of the dehydrated preparation 'Baliz' or a power-predried form of the preparation 'Baliz', or an active substance pre-recovered from the preparation 'Baliz' in the form of comenic acid or its salts, and also a base representing fatty substances, and a food or medicinal emulsifier. EFFECT: higher therapeutic clinical effectiveness in gynecologic and proctologic diseases by reducing tissue inflammatory processes, hypostasis events, itching, burning and providing longer remission period. 4 cl, 3 ex
The invention relates to medicine and the pharmaceutical industry and the development of a medicinal product in the form of rectal and vaginal suppositories for the treatment of proctologic diseases, such as external and internal hemorrhoids, rectal fissures, chronic anal fissures, shinkaryov, erosions on the surface of internal hemorrhoids, chronic hemorrhoids, thrombosis of hemorrhoids, hemorrhoidectomy, acute paraproctitis, and various gynecological diseases, such as inflammatory diseases of the vagina, acute vaginitis, bacterial vaginosis. Known suppositories "Basis" for the treatment of proctologic diseases containing drug Beliz-2, representing a multicomponent mixture of carbohydrate ketoacids, in particular a mixture of katalogowy acids, lactones of these acids, and acid number of gamma-pyrone, and Superin-M as the basis. (EN 2076696 C1, A61K 9/02, AK 31/71, 1997) The disadvantages of the known suppositories are not high enough quality, leading to kashimashi suppositories and, ultimately, to their disintegration, not a high therapeutic effect and a narrow spectrum of activity, namely the use only for the treatment of hemorrhoids. The closest essential prize is akov to the proposed suppositories are rectal suppositories "Basis" for the treatment of proctologic diseases, containing the drug Bales and a mixture of confectionery fat, frying fat and emulsifier of Apol taken as the basis. (EN 2337666 C1, AC 9/02, AK 31/191, AR 9/14, 10.11.2008.) These suppositories have not sufficiently high anti-inflammatory activity, not allowing to arrest the inflammatory processes in tissues, low remission in cases of chronic diseases and narrow spectrum of activity, namely only for the treatment of proctologic diseases. The present invention is the development of suppositories broad-spectrum with enhanced anti-inflammatory activity, allowing to arrest the inflammatory processes in tissues, the phenomenon of swelling, itching, burning in anal and female genital area, and to increase the period of remission for up to 6 months in cases of chronic gynecological and proctological diseases. The technical result is reflected in increased therapeutic efficacy of the treatment of gynecological and proctological diseases through the reduction of inflammatory processes in tissues, the phenomena of swelling, itching, burning, and increase remission of chronic diseases to 6 months. The problem is solved in that the suppositories for the treatment of proctologic and gynecological diseases, including prep the rat "Basis" and the basis according to the invention, they contain dehydrated form in the concentrated form of the drug "Basis" in the amount of 0.14 g or dried powdered form of the drug "Basis" in the amount of 0.9 grams, or isolated from drug Beliz" Kamenovo acid or a salt thereof in the amount of 0,0084 g suppository mass of 2.0, In addition, as the basis suppositories contain fatty substances and food or medical emulsifier. Fatty substances selected from the group: witepsol, supportin, hydrogenated fats, animal fats, solid fats type a, b, C. Food emulsifier selected from the group of Apol, lecithins, mono - and diglycerides of fatty acids, esters of glycerol and fatty organic acids, Palsgaard 0093. Medical emulsifier selected from the group T-2, saponin, anionic surfactants (Soaps), nonionic surfactants (tween-80), calcium stearate, pentol, sorbifolia. Suppositories prepared as follows. Take in a given quantity of a fatty substance selected from the group: witepsol, supportin, hydrogenated fats, animal fats, solid fats type a, b, C, and food emulsifier, selected from the group of Apol, lecithins, mono - and diglycerides of fatty acids, esters of glycerol and fatty organic acids, Palsgaard 0093, or medical emulsifier selected from the group: T-2, saponins, Ani is by surfactants (Soaps), nonionic surfactants (tween-80), calcium stearate, pentol, sorbifolia. Download these main components in a container, heated to 65-70°C. to obtain a molten mass. The molten mass is stirred for 10 min to obtain a homogeneous mass. Add to the melt in terms of one suppository: pre-dehydrated form of the drug Basis" in the form of a concentrate in the amount of 0.14 g, or pre-dried form of the drug Basis" to a powder in the amount of 0.9 grams, or pre-selected active substance of the medicinal product "Basis" in the form of Kamenovo acid or a salt thereof in the amount of 0,0084, Mix these components for 20 min to obtain a homogeneous mass. Then the temperature suppozitornoj mass is brought to 42-45°C and stirred for 30 minutes Take samples for analysis. The resulting mass is fed to the molding in special for suppositories forms, pre-cooled and washed with a soap solution or spirtovm solution of glycerol. Filled forms cool for 15-20 minutes, remove from moulds and Packed. Received suppositories have a high therapeutic efficacy in the treatment of gynecological and proctological diseases by inflammatory edema is x processes in tissues, phenomena of swelling, itching, burning, and increase remission of chronic diseases to 6 months. The invention is illustrated in the following examples. Example 1. For manufacturing fundamentals take a fatty substance selected from the group: witepsol, supportin, hydrogenated fats, animal fats, solid fats type a, b, C, and food emulsifier, selected from the group of Apol, lecithins, mono - and diglycerides of fatty acids, esters of glycerol and fatty organic acids, Palsgaard 0093. Download these main components in a container, heated to 65°C. to obtain a molten mass. The molten mass is stirred for 10 min to obtain a homogeneous mass. Added to the molten fatty substance the active substance of the drug Beliz - Kamenovo acid or its salts, previously isolated from a medicinal product "Bales". Mix these components within 20 minutes These components take in the city in terms of one suppository mass of 2.0 g:
Then the temperature suppozitornoj mass was adjusted to 42°C and stirred for 30 min to obtain a homogeneous mass. Take samples for analysis. The resulting mass is fed to the molding in special for suppositories forms, pre-cooled and washed with a soap solution or alcohol solution of glycerol. The filled form is cooled for 15 minutes, remove suppositories form and Packed. Example 2. For manufacturing fundamentals take a fatty substance selected from the group: witepsol, supportin, hydrogenated fats, animal fats, solid fats type a, b, C, and food emulsifier, selected from the group of Apol, lecithins, mono - and diglycerides of fatty acids, esters of glycerol and fatty organic acids, Palsgaard 0093. Download these main components in a container, heated to 70°C. to obtain a molten mass. The molten mass is stirred for 10 min to obtain a homogeneous mass. Added to the molten fatty substance and an emulsifier dehydrated form of the drug Basis" in the form of a concentrate. Mix these components within 20 minutes These components take in the city in terms of one suppository mass of 2.0 g:
Mix these components for 30 min to obtain a homogeneous mass. Then the temperature suppozitornoj mass is brought to 45°C and stirred for 20 minutes Take samples for analysis. The resulting mass is fed to the molding in special for suppositories forms, pre-cooled and washed with a soap solution or alcohol solution of glycerol. The filled form is cooled for 15 minutes, remove suppositories form and Packed. Example 3. For manufacturing fundamentals take a fatty substance selected from the group: witepsol, supportin, hydrogenated fats, animal fats, solid fats type a, b, C, and medical emulsifier selected from the group: T-2, saponin, anionic surfactants (Soaps), nonionic surfactants (tween-80), calcium stearate, pentol, sorbifolia. Download these main components in a container, heated to 70°C. to obtain a molten mass. The molten mass is stirred for 10 min to obtain a homogeneous mass. Added to the molten fatty substance and an emulsifier powder form of the drug Basis". Mix these components within 20 minutes These components take in the city in terms of one suppose the oriy weight of 2.0 g:
Mix these components for 30 min to obtain a homogeneous mass. Then the temperature suppozitornoj mass is brought to 45°C and stirred for 20 minutes Take samples for analysis. The resulting mass is fed to the molding in special for suppositories forms, pre-cooled and washed with a soap solution or alcohol solution of glycerol. The filled form is cooled to 20 minutes, remove the suppositories form and Packed. The comparative analysis of suppositories obtained in examples 1, 2, 3, with a unique selection of component framework with suppozitornyj mass obtained on the prototype showed that suppozitornaja the weight of the claimed method, homogeneous, elastic, compact, does not crumble or disintegrate during use. The effectiveness of the treatment by suppositories made on the presented examples, was investigated in 3 groups of patients suffering from anal and gynecological diseases, 10 people each. The first group of patients (control prototype)suffering from proctologic diseases, the definition is about the daily introduction 1 suppository, made the prototype, 2 times a day morning and evening course 5 days. And the second group of patients with proctological diseases (such as external and internal hemorrhoids, fissures of the rectum, chronic anal fissure, sincerity, erosion on the surface of internal hemorrhoids, chronic hemorrhoids, thrombosis of hemorrhoids, hemorrhoidectomy, acute paraproctitis), and the third group of patients suffering from gynecological diseases (such as inflammatory diseases of the vagina, acute vaginitis, bacterial vaginosis), assigned to the introduction of suppositories which are manufactured according to examples 1, 2, 3, 1 suppository 2 times a day morning and evening course 5 days. As a result of treatment, there was statistically significant decrease in inflammatory processes in tissues, the phenomenon of swelling, itching, burning, reducing the number of pathological whiter, increasing the number of lactobacilli, improving the microflora of the vagina. At the control examination after 10 days it is established that in 2 and 3 groups of patients positive therapeutic result, which is manifested in the inflammation process, removing edema, itching, burning, subsidence of the pain, stop bleeding, occurred in 20-30 minutes after administration of suppositories, and full recovery occurred after stock in contrast to the control group, where therapeutic effect occurred on the 14th day. Observations have shown that anti-inflammatory activity of the claimed suppositories reduces to twice the duration of treatment of inflammatory proctologic diseases and pelvic inflammatory disease (up to 7 days) compared to the prototype (up to 14 days). At the control examination after 6 months of complaints from patients suffering from chronic inflammatory proctologic and gynecological diseases, have been reported. During the survey it was noted achieve a positive result in all treated patients. Ultrasound examination confirmed the removal of inflammation. When assessing the toxicity of the drug was conducted an experiment on rats clean Wistar daily rectal 200 mg suppozitornoj mass while simultaneously placebo-control group of 50 and 10 animals, respectively). Evaluation of the effects of the drug were conducted over the course of the introduction on the General condition of the animals, immediately after completion of the course introduction, and after 2 weeks on the biochemical parameters of blood, peripheral blood and blood coagulability and conduct morphometric analysis and histopathological studies of the internal organs of animals. The experiments were conducted on four experimental the of the other groups of 10 females and 10 males in each group. The excess of the injected dose up to 5 times does not lead to pathological changes in the body. Within 9 days (treatment) there were no reported deaths or acute poisoning. Biochemical parameters remained within the normal range (total protein, the ratio of protein fractions and total serum cholesterol, glucose, urea, creatinine, the activity of alanine and aspartate transaminases, alkaline phosphatase). Histological examination of the organs did not reveal any deviations in their structure. Thus, the proposed suppositories for the treatment of proctologic and gynecological diseases eliminate the disadvantages associated with the use of known suppositories, and to improve therapeutic efficacy of treatment due to edema in the short term inflammatory processes in tissues, the phenomenon of swelling, itching, tingling, painless insertion of suppositories, which helps to prolong the remission period up to 6 months in cases of chronic diseases. Clinical studies have allowed us to draw the following conclusions. The use of declared suppositories achieve a high therapeutic effect in the treatment of a wide spectrum of proctologic diseases, such as external and internal hemorrhoids, rectal fissures, chronic the x anal fissures, sphincteric, erosions on the surface of internal hemorrhoids, chronic hemorrhoids, thrombosis of hemorrhoids, hemorrhoidectomy, acute paraproctitis, and various gynecological diseases, such as inflammatory diseases of the vagina, acute vaginitis, bacterial vaginosis. The choice of components and their quantitative values gives an opportunity to gain new technical result, which is manifested in the reduction of inflammatory processes in tissues as in proctology, and in the female genital area, and the increase of remission in cases of chronic gynecological and proctological diseases. The tool is well tolerated and does not cause allergies and other side effects during treatment. In addition, suppositories stable during storage, resist the action of air, light and high temperatures, which gives an opportunity to choose the optimum conditions of the technological process of their production. Thus, the claimed rectal and vaginal suppositories comply with the requirements of normative-technical documentation as suppositories are effective and safe drug and can be recommended for clinical use in patients with proctological and gynecological diseases. 1. Soup is sicarii for the treatment of proctologic and gynecological diseases, containing the drug and a base, characterized in that they contain as a medicinal product previously dehydrated form of the drug Basis" in the form of a concentrate in the amount of 0.14 g in terms of one suppository or pre-dried to a powder form of the drug Basis" in the amount of 0.9 g in terms of one suppository, or pre-allocated out of the drug Beliz active substance in the form of Kamenovo acid or its salts in the number 0,0084 g in terms of one suppository, and as the basis they contain fatty substances and food or medical emulsifier. 2. Suppositories according to claim 1, characterized in that as fatty substances they contain components selected from the group: witepsol, supportin, hydrogenated fats, animal fats, solid fats type a, b, C. 3. Suppositories according to claim 1, characterized in that as a food emulsifier they contain components selected from the group: Apol, lecithins, mono - and diglycerides of fatty acids, esters of glycerol and fatty organic acids, Palsgaard 0093. 4. Suppositories according to claim 1, characterized in that the quality of medical emulsifier they contain substances selected from the group T-2, saponin, anionic surfactants (Soaps), nei is ngenye surfactants (tween-80), calcium stearate, pentol, sorbifolia.
|
|||||||||||||||||